CJC-1295 with DAC

What CJC-1295 with DAC does

CJC-1295 with DAC is an experimental injection that raises growth hormone and IGF-1 for days. Small human studies measured hormones, not muscle gain, recovery or longevity. An HIV trial stopped early and has no published results. Flushing, headaches and injection reactions were frequent. It has no FDA approval.

• In small studies, one shot raised growth hormone and IGF-1 for days; muscle gain and recovery were not tested. (Studied in a trial)
• With weekly or every-other-week shots, IGF-1 levels stayed raised in a small study. (Studied in a trial)
• People report using it for muscle, body shape, skin, sleep and injury recovery. (Reported by users)
• Individual users report better mood, energy, strength or endurance; this does not show the drug caused it. (Reported by users)

Uses in the sources

• Studied for GH and IGF-1 release in healthy adults; a terminated HIV visceral-fat study has no posted results. (Studied in a trial) (source)
• People report use for muscle and body composition. Controlled trials have not established these benefits. (Reported by users) (source)
• Reported for exercise and injury recovery; hormone increases do not establish faster healing. (Reported by users) (source)
• Sleep improvement is a reported reason for use, not an established treatment effect. (Reported by users) (source)

CJC-1295 with DAC dosage

Typical reported dose: 1–2 mg total per week

• One trial injection: 30 mcg/kg: 30 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
• One trial injection: 60 mcg/kg: 60 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
• One trial injection: 125 mcg/kg: 125 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
• One trial injection: 250 mcg/kg: 250 mcg/kg once on day 0 once only, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; research hormone-response study. (source)
• 30 mcg/kg every 14 days, two doses: 30 mcg/kg on days 0 and 14 once every 14 days, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; five active recipients per arm. (source)
• 60 mcg/kg every 14 days, two doses: 60 mcg/kg on days 0 and 14 once every 14 days, under the skin. Studied in a trial. Studied in: Healthy adults ages 21–61; five active recipients per arm. (source)

Highest studied: Published weekly arm: 30 mcg/kg on days 0, 7 and 14; body weight is needed for an mg comparison..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix CJC-1295 with DAC

Comes as: Freeze-dried powder vial; no approved CJC injection product..

Mixed with: Community reports use bacteriostatic water; no approved CJC diluent or home-mixing instruction exists..

Common vial sizes: 2 mg. Common water amounts: 1, 2 mL.

• A cited post discusses 2 mg with 1 mL; another suggests 2 mL. These are reports, not validated formulations.
• DAC and ipamorelin have different exposure profiles. A fixed blend prevents independent adjustment.
• Water volume changes concentration, not milligrams. Do not copy syringe units from a different vial.
• Bacteriostatic water does not sterilize contaminated powder. Clear appearance cannot establish sterility.

Before mixing: Supplier reports summarized by FDA describe −20°C powder storage. No approved consumer storage schedule exists.

After mixing: Reports summarized by FDA describe about 4°C. No validated beyond-use date for community mixtures was found.

CJC-1295 with DAC side effects and risks

Reported side effects

• Injection-site irritation, redness, pain or itching: About 70% active in the single dose trial; all 20 active in the repeat dose trial; placebo redness 3/4 in repeat dosing., mild. Check persistent or spreading redness; fever, pus or severe pain needs urgent assessment. (source)
• Headache: Single dose: 63% active versus 14% placebo. Repeat dosing: 20–80% across active groups versus 50% placebo., moderate. Severe headache or vision change needs urgent care. (source)
• Diarrhea: 43% active versus 0% placebo; 45% at 125 and 100% at 250 mcg/kg in the published report., moderate (source)
• Flushing, warmth or transient low blood pressure: Single dose: 30% active, 0% placebo. Repeat dosing: flushing 40–100%, depending on dose., moderate. Fainting, chest pain or persistent fast heart rate needs urgent assessment. (source)
• Local hives: Almost 30% of active recipients in the single dose trial., moderate. Widespread hives, throat swelling or breathing trouble is an emergency. (source)
• Nausea or abdominal pain: 20% reported in the trial paper; placebo 0%. Exact pooled denominator was not clear., moderate (source)
• Faster heart rate: Dose related in the 12 man pulse study; counts and rates unavailable., moderate (source)
• High blood sugar, swelling or joint pain: Seen with related tesamorelin; CJC rates remain unknown. Short DAC trials found no consistent blood sugar change., moderate (source)
• Serious allergic or immune reactions: FDA identifies immunogenicity concerns; frequency with repeated exposure is unknown., serious (source)
• Fatal heart attack during a trial: One death after dose 11 in the terminated HIV trial. Causation and a reliable incidence rate are unresolved., serious (source)

Stop and get help if

• Trouble breathing, throat or face swelling, widespread hives, or collapse: Stop using CJC-1295 and call emergency services now.
• Chest pain, fainting, severe breathlessness, or a sustained racing heart: Stop exposure and seek emergency care now.
• Severe headache with vision change, vomiting, or new weakness: Get emergency care now; do not assume this is normal flushing.
• Rapid swelling or weight gain with shortness of breath: Seek urgent care now for possible fluid overload or heart problems.
• Hot spreading injection-site redness, severe pain, pus, or fever: Stop injections and get urgent same-day care; fever or rapidly worsening illness needs emergency care.
• Confusion, vomiting, marked thirst or urination, or low sugar that does not improve: Check blood sugar if available and seek urgent care; severe confusion or unconsciousness needs emergency services.

Who should avoid it

• pregnant: CJC pregnancy safety is unknown. Stop use during pregnancy.
• breastfeeding: Milk transfer and infant effects are unknown; avoid exposing a nursing infant.
• tryingToConceive: Fertility and early-pregnancy effects are unknown. This is a precautionary screen.
• under18: FDA found no safety data in children. Growth hormone stimulation can affect growth.
• activeCancer: Growth hormone can support cell growth. Avoid CJC with active cancer, following related-drug precautions.
• cancerHistory: A prior cancer needs individual review; long-term recurrence risk with CJC is unknown.
• other: Excess growth hormone makes CJC unsuitable; pituitary disease needs specialist review.
• other: A serious allergy to CJC or its vial ingredients means avoiding further use.
• diabetes: Growth hormone can raise blood sugar. Diabetes was excluded from the HIV study; direct safety data are lacking.
• diabeticRetinopathy: Related tesamorelin guidance warns about worsening diabetic eye disease; CJC-specific risk is unknown.
• heartCondition: Heart-rate and blood-pressure changes matter with heart disease; longer-term cardiac safety is unknown.
• uncontrolledBloodPressure: Blood-pressure instability and GH-related fluid retention warrant review before further exposure.
• sleepApnea: Sleep apnea raises baseline cardiometabolic risk; new snoring or breathing pauses need assessment.
• kidneyDisease: No kidney dosing study was found. Kidney disease can also cause swelling and change hormone tests.
• liverDisease: No liver dosing study was found; liver disease can distort IGF-1 blood tests.
• surgeryPlanned: Tell the anesthesia team about peptide and other hormone use; no perioperative CJC safety study was found.
• testedAthlete: WADA prohibits GHRH analogues at all times, including CJC-1295.

Interactions

• Insulin: A related drug, tesamorelin, can raise blood sugar. CJC effects on insulin needs are unknown; review readings when exposure starts or stops.
• Sulfonylureas: CJC interactions are unknown. These medicines can cause severe low blood sugar; review readings with your clinician when CJC starts or stops.
• Other GH, GHRH or ghrelin-pathway drugs: Effects may add, raising IGF-1 or glucose and fluid-retention concerns. No CJC/ipamorelin combination trial was found.
• Glucocorticoid replacement: Tesamorelin's label warns growth hormone can lower cortisol and change steroid replacement needs. This is untested with CJC.
• Medicines affected by liver CYP enzymes: Tesamorelin's label warns growth hormone may change drug breakdown. CJC interactions and medication adjustments are unknown.
• Anticoagulants: Blood thinners increase bleeding and bruising from needle punctures. A direct CJC drug interaction has not been demonstrated.

Product quality risks

• DAC and no-DAC names are confused. FDA considers them different active moieties with different safety and exposure profiles.
• FDA found missing impurity, aggregate and endotoxin data in reviewed certificates. A high purity percentage alone cannot show injection safety.
• A 2010 seized sample contained a 29-amino-acid peptide consistent with the short form sold as CJC-1295; it was not proof of DAC identity.
• A 2019 seizure study identified glycine-added modified GRF and other secretagogues. Seized material is not a representative market survey.
• Regulators warn unapproved peptide vials may have too much, too little or no stated ingredient, particles, microbes or endotoxin.

What to expect

Three small published studies and one stopped HIV trial. A protein report reused participants; health benefits remain unproven.

Key studies

• Teichman 2006: one dose: One DAC injection raised GH and IGF-1 for days; it did not test muscle gain, fat loss or recovery. (source)
• Teichman 2006: repeat doses: Weekly or fortnightly DAC dosing accumulated and kept IGF-1 elevated; long-term outcomes were not tested. (source)
• Ionescu 2006: GH pulses: DAC preserved detectable GH pulses while raising the trough; this does not prove safety of sustained stimulation. (source)
• Sackmann-Sala 2009: blood proteins: An exploratory analysis found possible hormone-response markers, not better health or performance. (source)
• HIV visceral-fat trial: terminated: The terminated study supplies no usable benefit estimate or established safe weekly maximum. (source)
• Jetté 2005: albumin binding: Animal and cell work supports a long-lasting GHRH analogue; it does not validate community products. (source)

CJC-1295 with DAC FAQ

• Is CJC-1295 with DAC FDA-approved? No approved CJC product or dose label. Withdrawal from Category 2 did not establish approval or a Category 1 compounding pathway.
• How do people take it? Under the skin, once weekly. Reported cycles: 8–12 or 12–16 weeks on, then 4–6 weeks off. Reports describe 8–12 or 12–16 weeks. Source: reported by users, not an established dose.
• What's the difference between CJC-1295 with DAC and Ipamorelin? CJC-1295 with DAC: an experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit. Ipamorelin: an experimental peptide that triggers growth hormone release. Why people pair them: users combine GHRH and ghrelin signals hoping for a larger GH response. No human CJC/ipamorelin combination trial was found.
• Can I take it with Ipamorelin? Users combine GHRH and ghrelin signals hoping for a larger GH response. No human CJC/ipamorelin combination trial was found. Possible additive GH/IGF-1 and glucose effects; safety and benefit are untested. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Growth hormone releasing factors, including GHRH analogues. Covers DAC and modified GRF 1-29.
• How long does a mixed vial last? Reports summarized by FDA describe about 4°C. No validated beyond-use date for community mixtures was found.